Poly Medicure Limited

rs,

- POL YMED The Manager, BSE Limited, Department of Corporate Services, Phirozee Jeejeebhoy Towers, Dalal Street, Mumbai- 400001. The Manager National Stock Exchange of India Limited Exchange Plaz

15%

team with in place in all focus geographies  Upscale R&D and operations 2 Year revenue CAGR of 15% (FY18 – FY20) higher than both Indian medical devices growth (9%)2 and exports market growth (13%)

9%

erations 2 Year revenue CAGR of 15% (FY18 – FY20) higher than both Indian medical devices growth (9%)2 and exports market growth (13%) 4 PBT margin of 18.2% (FY20), with PBT CAGR of 13.9% over last 2

13%

15% (FY18 – FY20) higher than both Indian medical devices growth (9%)2 and exports market growth (13%) 4 PBT margin of 18.2% (FY20), with PBT CAGR of 13.9% over last 2 years (FY18 – FY20)  Transitio

18.2%

gher than both Indian medical devices growth (9%)2 and exports market growth (13%) 4 PBT margin of 18.2% (FY20), with PBT CAGR of 13.9% over last 2 years (FY18 – FY20)  Transition to a solution provide

13.9%

evices growth (9%)2 and exports market growth (13%) 4 PBT margin of 18.2% (FY20), with PBT CAGR of 13.9% over last 2 years (FY18 – FY20)  Transition to a solution provider, in order to become a prefer

17%

g Facilities Globally +1 R&D unit; Manufacturing well entrenched close to markets 2 Yr PAT CAGR 17% With 2 Yr Revenue CAGR of 15% Notes: 1. 2. CRISILl Report As at December 31, 2020 w w w . p o l

1.5x

Devices Players in India by Revenue1 Highly Awarded and Recognized Revenue from operations (FY19) 1.5x of nearest competitor 48,970 28,700 6,108 4,070 3,280 2,930 Philips India Siemens Po

30%

re Trivitron Sahajanand Medical Allengers Exporter with High Brand Equity Revenue Mix (FY20) 30%  Distribution network spread over 110 different countries  Strong presence in India  Growth e

70%

ries  Strong presence in India  Growth expansion in Europe  Balanced sales throughout the world 70% Export India Notes: 1. Source: CRISIL, revenue compared for FY19 w w w . p o l y m e d i c u r

rs1

of distributors  Distribution network with a pan-India  presence included over 260 distributors1 Involved in promotion of our products in over 5,000 private and government hospitals and nursing h

10.0%

ATORS PROVIDES HUGE OPPORTUNITY India’s GDP growth to be greater than global growth % growth YoY 10.0% 5.0% 6.0% 4.0% 6.2% 3.6% 4.2% 2.8% -4.0% -7.7% FY20 FY21P FY22P FY23P FY24P India W

Notes

5

Registered Office

1

Notes

1. 2. 3. 4. Recognized by the Plastics Exports Promotion Council, sponsored by the Ministry of Commerce and Industry, Department of Commerce, the Government of India Source: CRISIL report One of the facilities is operated by an associate company Financial statements and investor presentation (October 2020) w w w . p o l y m e d i c u r e . c o m 3 C o n f i d e n t i a l OUR JOURNEY…..…..MILESTONE ACHIEVEMENTS 1997 Commencement of Manufacturing Operation 2002 JV in Egypt 2009 China Plant 2011 Company Listed in NSE 2014 New Plant at SEZ Jaipur 2016 New R&D Center *2020 IMT Faridabad expansion Phase II *2021 SEZ Jaipur expansion Phase II w w w . p o l y m e d i c u r e . c o m *Work in progress 4 C o n f i d e n t i a l CORPORATE STRUCTURE INDIA Poly Medicure Ltd POLYMED GROUP OVERSEAS Poly Medicure (Laiyang) Co. Ltd. - China - Wholly owned Subsidiary Poly Medicure BV - Netherlands - Wholly owned Subsidiary Ultra for Medical Products Co. (UMIC) - Egypt Associate Plan 1 Health India Pvt.

Notes

1. 2. CRISILl Report As at December 31, 2020 w w w . p o l y m e d i c u r e . c o m 6 C o n f i d e n t i a l LEADERSHIP POSITION AS AN INDIAN EXPORTER Among Top 2 Medical Devices Players in India by Revenue1 Highly Awarded and Recognized Revenue from operations (FY19) 1.5x of nearest competitor 48,970 28,700 6,108 4,070 3,280 2,930 Philips India Siemens Poly Medicure Trivitron Sahajanand Medical Allengers Exporter with High Brand Equity Revenue Mix (FY20) 30%  Distribution network spread over 110 different countries  Strong presence in India  Growth expansion in Europe  Balanced sales throughout the world 70% Export India

Notes

1. Source: CRISIL, revenue compared for FY19 w w w . p o l y m e d i c u r e . c o m Top Exporter Of Plastic Medical Disposables/ Surgical Items for 2018 – 2019 Indian Medical Device Company of the Year 2018 By DoP, Govt. of India Industrial Innovation Award By Confederation of Indian Industries (2019) Asia’s 200 Best Under a Billion By Forbes Magazine 7 C o n f i d e n t i a l WELL ENTRENCHED OPERATIONS ACROSS 112 COUNTRIES1 8 Manufacturing Plants 1 R&D Center  Long tenured relationships with strategic network of distributors  Distribution network with a pan-India  presence included over 260 distributors1 Involved in promotion of our products in over 5,000 private and government hospitals and nursing homes across India, as on December 31, 2020 UNIQUELY POSITIONED TO PROVIDE VALUE TO OUR CUSTOMERS

Notes

1. As on December 2020 w w w . p o l y m e d i c u r e . c o m 8 C o n f i d e n t i a l FAVOURABLE MACRO INDICATORS PROVIDES HUGE OPPORTUNITY India’s GDP growth to be greater than global growth % growth YoY 10.0% 5.0% 6.0% 4.0% 6.2% 3.6% 4.2% 2.8% -4.0% -7.7% FY20 FY21P FY22P FY23P FY24P India World  Base effect and rising global tide effect key short term driver  Growing working population and urbanization long term drivers Healthy growth in income levels driving consumption growth 68,572 72,805 77,659 82,931 87,828 92,085 94,954 6 Yr CAGR of 5.6% Rising income levels contributing to fast growing private consumption expenditure in Healthcare 7 Yr CAGR of 13% 49,359 90,546 1,01,443 1,13,059 FY12 FY17 FY18 FY19 Private Final Consumption Expenditure in Healthcare (INR Bn)  Higher affordability driving demand for quality healthcare Public Healthcare expenditure is low, with private sector accounting for bulk Hospital Beds/ 10,000 population 12 19 21 21 25 26 29 81 43 FY14 FY15 FY16 FY

Notes

1. w w w . p o l y m e d i c u r e . c o m As on December 2020 Portfolio of more than 130 SKUs of Disposable Medical Devices1 13 C o n f i d e n t i a l CONTINUED INNOVATION THROUGH RICH PIPELINE VTM & VLTM Kits Dialysis Machines N 95 Masks Pre-Filled Syringes Vial Access Spike with Valve Single use Dialyzers 1.4 / 1.6 / 1.8 Blood Collection Needles with Flashback Launched in May 2020 Launched in July 2020 Launched in Aug 2020 Launched in Nov 2020 Launched in Dec 2020 Numerous products in pipeline for the next 3 years including premium products for both high value and fast growing markets w w w . p o l y m e d i c u r e . c o m Launch by Jan 2021 Launch by Feb 2021 14 C o n f i d e n t i a l ROBUST R&D, REGULATORY AND PROCESS CAPABILITIES FULLY INTEGRATED FROM NEW PRODUCT DESIGN DEVELOPMENT TO AUTOMATED MANUFACTURING  300+ Patents & 190+ pending applications  R&D Team with 35 engineers and 10 Clinical Consultants  All facilities are EC certified F u l l y i n t e g r a t e d f r o m

Registered Office

232 B, 3rd Floor, Okhla Industrial Estate, Phase III, New Delhi-110020, India Tel:- 91-11-33550700, 47317000, 26321838/99 For any general queries, Reach us at: info@polymedicure.com Visit: www.polymedicure.com w w w . p o l y m e d i c u r e . c o m C o n f i d e n t i a l